Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amarin Accelerates Timeline For NDA Filing Of AMR101

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Positive results from a Phase III trial of Amarin Corporation's triglyceride-lowering drug AMR101 will allow the company to submit its NDA to FDA in 2011, a year ahead of schedule.

You may also be interested in...



Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?

Omega-3 fish oils, once exclusive to the realm of dietary supplements, increasingly are swimming upstream into prescription drugs – a trend with both positive and negative implications for supplements.

Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?

Omega-3 fish oils, once exclusive to the realm of dietary supplements, increasingly are swimming upstream into prescription drugs – a trend with both positive and negative implications for supplements.

Amarin Moves Beyond Bridge Financing With $70 Million Private Placement

Existing and new investors are drawn by the potential of a compound that would compete with statins in the dyslipidemia market.

Topics

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel